Halide Sedef Karaman

TL;DR: Induced fit docking process performed on the compounds inhibiting hCA I, hCA II, AChE, and BChE receptors will be useful for design of more potent and selective inhibitors against the enzymes.

TL;DR: The inhibition profile of the new pyrazoline compounds at the receptors was determined and these compounds were effective inhibitor compounds of the human carbonic anhydrase I and II isozymes and of the acetylcholinesterase (AChE) enzyme.

TL;DR: Overall, the results strongly supported the promising nature of the enantiomerically enriched oxazolidinones as selective hCA, AChE, and α-glycosidase inhibitors as promising drug candidates for the treatment of diseases like glaucoma, leukemia, epilepsy; Alzheimer's disease; type-2 diabetes mellitus.

TL;DR: The inhibition type of the 1H-pyrazolo[1,2-b]phthalazine-5,10-dione derivatives at the receptors was determined and the data obtained in this work was evaluated.

TL;DR: The findings of in vitro and in silico evaluations indicate 4-(diethylamino)-salicylaldehyde-based thiosemicarbazone scaffold to be a promising hit for drug development for multifactorial diseases like Alzheimer's disease.